key: cord-0816603-2xy2g6qo
authors: Lowe, A.; Pararajasingam, A.; Ali, F.M.; Dawood, S.; Lowe, C.D.; Stone, N.M.
title: A new virtual inpatient dermatology electronic referral service: a timely solution in the COVID‐19 pandemic and beyond?
date: 2021-04-18
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17257
sha: c355446c85c5a5ca045561baab267b6ceea4e580
doc_id: 816603
cord_uid: 2xy2g6qo

The use of teledermatology in an inpatient setting is not well-established, with limited data published compared to the outpatient setting. It has, however, been demonstrated that teledermatology may be effective for managing inpatient dermatologic disease, leading to highly concordant diagnostic and management decisions(1,2). Involvement of dermatologists in the care of hospitalized patients has been found to improve patient outcomes(3) with inpatient teledermatology reducing response times(4).

A new virtual inpatient dermatology electronic referral service: a timely solution in the COVID-19 pandemic and beyond?

Dear Editor, The use of teledermatology in an inpatient setting is not well-established, with limited data published compared to the outpatient setting. It has, however, been demonstrated that teledermatology may be effective for managing inpatient dermatologic disease, leading to highly concordant diagnostic and management decisions. 1,2 Involvement of dermatologists in the care of hospitalized patients has been found to improve patient outcomes 3 with inpatient teledermatology reducing response times. 4 We set up a store-and-forward, fully digitized, virtual inpatient referral service to replace our traditional paper-based, faceto-face (FTF) inpatient referral pathway, amidst the COVID-19 pandemic. Our health board in Wales, UK, covers a relatively wide geographical area across 1553 km 2 , accounting for 30% of the Welsh landmass, but covering only 18% of the population of 3.1 million. We cover inpatients across six different hospital sites, two of which have traditionally had inequitable access to a dermatology opinion as they lack regular onsite clinics. The old system was onerous for both clinicians and administrative staff, as historically inpatient referrals comprised handwritten forms manually delivered or faxed between hospitals. Referrals often lacked vital clinical information, comprised illegible handwriting and frequently went missing. We therefore implemented an entirely paperless, electronic referral pathway that integrated with the electronic patient record (EPR) and enabled virtual rather than FTF review.

An e-referral form was designed for referrers to include essential clinical information, with medical photographs requested alongside. High-quality images were taken by the medical illustration service and uploaded securely onto the EPR. Dermatology residents reviewed referrals virtually, relaying advice back to the referring clinician. Referrals, including patient metadata, from all inpatient specialties across the six hospitals over a 10-week period from 14 July to 30 September 2020 were assessed. A five-point Likert scale was used to assess the degree of confidence residents felt in managing inpatients virtually.

Of 95 consecutive referrals, 55% were male and 45% female (age range 0-103 years; average 63.8). Almost all (96%) were judged to be appropriately directed to dermatology. Most referrals (84%) were successfully dealt with virtually. The majority of the remaining 16% comprised patients that required a biopsy, paediatric cases needing parental reassurance and complex medical cases. A wide variety of dermatological conditions were diagnosed and managed, both inflammatory and lesions, and 87% were discharged with appropriate advice.

The average response time was 1.9 days, 66% were dealt with within 24 h and 77% within 48 h (Fig. 1a) . The rate-limiting step was waiting for accompanying images, accounting for 74% of variance in the time awaiting review (Fig. 1b) . Residents felt highly confident in 62% cases (Fig. 1c) . A senior review was needed in 65%, of which 99% were easy to obtain.

Our virtual platform has widened the reach of timely specialist input across sites where dermatology services have not traditionally been based, ensuring equitable access for patients, independent of location. It establishes a secure and permanent digital record, enabling effective handover of acutely unwell inpatients (Table 1 ). This format also lends itself to peer review of images and virtual ward rounds, 5 and therefore contributes substantially to the education and training of residents, particularly in meeting their teledermatology training needs, 6,7 a boon during the pandemic wherein resident training has unavoidably Table 1 Benefits and limitations of a new virtual electronic inpatient dermatology referral service versus a paper and face-to-face (FTF) system

Faster access to dermatology opinions for inpatients Access to photographs rate-limiting step All essential clinical details fully included in e-referral Accuracy of diagnosis reliant on quality of photographs Automatic paper trail (no referrals physically misplaced) Need to convert to FTF for some patients if diagnosis unclear and/or biopsy required been impacted by altered patient flow. Until COVID-19, teledermatology was underutilized in the inpatient setting. FTF review remains the gold standard for inpatient consultations. Nonetheless, we conclude that most inpatient referrals can be confidently managed virtually, thereby increasing efficiency, reducing response time and obviating the need for FTF ward visits in a safe, timely and equitable manner. This is particularly significant in our current climate, reducing the attendant risk of cross-contamination between sites.

Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease

Implementing and optimizing inpatient access to dermatology consultations via telemedicine: an experiential study

Association of dermatology consultation with accuracy of cutaneous disorder diagnoses in hospitalized patients: a multicenter analysis

Teledermatology as a means to improve access to inpatient dermatology care

Inpatient teledermatology during the COVID-19 pandemic

A UK-wide survey looking at teaching and trainee confidence in teledermatology: a vital gap in a COVID-19-induced era of rapid digital transformation

A paradigm shift in trainee confidence in teledermatology and virtual working during the COVID-19 pandemic: results of a follow-up UK-wide survey

Good tolerance of hyaluronic acid injections during the period of the COVID-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study Dear Editor, Dermatologists have questioned the possibility of continuing hyaluronic acid (HA) injections during the COVID-19 pandemic period, fearing especially an increase in immune complications. Therefore, the Group for Aesthetic and Corrective Dermatology of the French Society of Dermatology (gDEC) decided to set up a prospective, clinical study over the period May to July 2020 to follow a large patient cohort being injected with HA during the COVID-19 pandemic.Overall, 14 dermatologists working in France, Belgium and Switzerland participated in the study. Each physician included all patients during the observation period that received facial HA injections. Participating physicians were encouraged to treat all patients according to their usual practice. Due to the COVID-19 pandemic, the hygiene measures were reinforced by the use of hydroalcoholic gel of physician and patient and the practitioners wearing a FFP2 masks at all times during the patient encounters. All products injected were commercially available within Europe and were purchased by the physicians.Two types of side-effects were recorded: (i) patient selfreported side-effects at any time of the study, (ii) side-effects discovered during the systematic follow-up by the treating physician at 1 and 3 months after the treatment.A total of 1093 patients were included. Overall, 1927 syringes of HA were used, i.e. an average of 1.8 syringes per patient. 921 and 873 patients were reached, respectively, for the 1-and 3-month systematic follow-up. Ten patients with COVID-19 infection were injected later than 2 months after their infection. Five patients were diagnosed with an active COVID-19 infection within 3 months after their HA injection. 19 (1.7%) side-effects were reported, three self-reported and 16 (84% of side effect) observed at systematic follow-up. The recorded side-effects were those frequently associated with HA filler injections like erythema, oedema and temporary discomfort. They were all self-resolving within a few days and occurred in the absence of symptoms suggestive of COVID-19 infection. No further serious or unexpected sideeffects were reported. A summary of the results can be found in Table 1 .Our study shows an excellent tolerance of HA injections during the COVID-19 pandemic. No immune complications, that